



## **Prelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference**

January 4, 2022 12:00 PM EST

WILMINGTON, Del., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will present at the H.C Wainwright BioConnect Virtual Conference, being held on January 10-13, 2022.

The prerecorded presentation will become available on Monday, January 10, 2022 at 7:00 am ET and can be accessed by visiting the "Investors" page under the "[Events & Presentation](#)" section of the Prelude website, where a replay of the presentation will be available for a limited time.

### **About Prelude Therapeutics**

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative, potential best-in-class molecules targeting critical cancer cell pathways involved in cancer pathogenesis. Prelude's initial clinical candidates, PRT543 and PRT811, are potent, selective, oral PRMT5 inhibitors in Phase 1 development for the treatment of advanced solid tumors, primary and secondary CNS cancers and select myeloid malignancies. PRT1419, a potent and selective MCL1 inhibitor, is in Phase 1 development for patients with relapsed/refractory hematologic malignancies and solid tumors. PRT2527, a highly selective CDK9 inhibitor, is anticipated to begin Phase 1 clinical development by year-end as a monotherapy in patients with selected solid tumors. In addition, the Company's pipeline includes PRT-SCA2, a SMARCA2 protein degrader, PRT-K4, a highly selective kinase inhibitor, and additional discovery stage programs.

### **Investor Contacts:**

Stacey Jurchison  
Executive Director, Corporate Affairs  
[sjurchison@preludetx.com](mailto:sjurchison@preludetx.com)

Melissa Forst  
Argot Partners  
212.600.1902  
[prelude@argotpartners.com](mailto:prelude@argotpartners.com)

### **Media Contact:**

Paige Donnelly  
Argot Partners  
212.600.1902  
[prelude@argotpartners.com](mailto:prelude@argotpartners.com)